Efficacy of mosapride therapy on gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled cross-over study

Shengliang Chen,Ping Xu,Wei Gao,Jieru Ji,Liyan Zhang,Jianzhong Mo,Shudong Xiao
2008-01-01
Abstract:Background: Little data have been reported about the efficacy of mosapride, a gastrointestinal prokinetic agent, on gastroesophageal reflux symptoms and esophageal dysmotility in Chinese Han patients with gastroesophageal reflux disease (GERD). Aims: To investigate the efficacy of mosapride on GERD patients with Han nationality. Methods: Twenty-three GERD patients with typical gastroesophageal reflux symptoms were enrolled in this randomized, double-blind, placebo-controlled cross-over study. By gastroesophageal reflux symptom assessment, esophageal manometry and 24-hour monitoring of esophageal pH and refluxed bilirubin, the effects of 1-week cross-over treatment with mosapride on gastroesophageal reflux symptoms, esophageal dynamics and gastroesophageal reflux events were evaluated in comparison with placebo. Results: Compared with placebo-treated patients, mosapride therapy decreased significantly the total score of gastroesophageal reflux symptoms, increased the conduction velocity of peristaltic wave in esophageal body and the achievement ratio of wet swallow, and decreased the total times of pH<4 reflux events, times of long-term (≥5 min) reflux, percentage of total time with pH<4 and DeMeester score, as well as percentage of total time with bile reflux (P all <0.05). Conclusions: One-week mosapride therapy markedly improves the gastroesophageal reflux symptoms, and partially ameliorates the esophageal dysmotility as well as acid and bile reflux in Chinese Han GERD patients in this study. Mosapride is a safe and effective drug for GERD.
What problem does this paper attempt to address?